market access market access JULY/08/AUG
market access market access JULY/08/AUG
market access market access JULY/08/AUG
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>market</strong> <strong>access</strong><br />
Medical<br />
• Encourage industry to provide FDA with more data<br />
- Firms may voluntarily submit reports by third<br />
parties assessing conformance with appropriate<br />
international quality systems standards, such as<br />
ISO, which FDA would consider in setting our<br />
inspectional priorities<br />
In addition, Health Canada and the FDA undertook<br />
a cooperative effort to identify those device<br />
manufacturers in the US, who are due for an<br />
FDA inspection in 20<strong>08</strong> and at the same time are<br />
registered to ISO 13485 under the CMDCAS program.<br />
Manufacturers who met both criteria received a<br />
mailing with information about the pMAP program<br />
and were encouraged to participate.<br />
Most recently an increase of interest and participation<br />
in the program has been observed. In the Health<br />
Canada CMDCAS RBF (Registration Body Forum)<br />
meeting in May 20<strong>08</strong> it was stated that already five<br />
companies have been successfully assessed under<br />
the pMAP process. Both Health Canada and the FDA,<br />
which also participated in this meeting expressed that<br />
they remain committed to the program and agreed that<br />
a sample size of 10 successful pMAP audits would be<br />
considered “sufficient experience” to assess the results<br />
ConTInUeD on pAge 13<br />
JulY/<strong>08</strong>/aug<br />
Update on FDA’s Third Party Inspection Program and pMAP (continued)<br />
of this pilot program. If the assessment concludes that<br />
multi-purpose audits are valid and acceptable to fulfill<br />
the requirements under the CMDCAS program, then<br />
some of the restrictions for participation might be<br />
eliminated.<br />
Another very promising objective, which came out of<br />
this meeting, is the development of a common audit/<br />
inspection report format. A common report format<br />
would significantly reduce the time needed by the AP/<br />
Registrar to prepare the two submissions and hence<br />
would reduce the additional service fees associated<br />
with AP/pMAP audits.<br />
Who should participate and why?<br />
Manufacturers who are likely to be inspected by the<br />
FDA and who <strong>market</strong> products in foreign countries will<br />
benefit from participation in the AP and pMAP program<br />
because they will reduce the overall number of audits/<br />
inspections conducted at their establishment and they<br />
will gain more control over the timing and planning of<br />
the audit/inspection.<br />
Manufacturers who in the past have not been inspected<br />
at two year intervals might want to consider an AP<br />
inspection for another reason: Historic data shows<br />
that regularly inspected establishments are more<br />
likely to be found in compliance with the regulations.<br />
By requesting an AP inspection on a regular basis,<br />
manufacturers can increase the confidence in their<br />
quality management system and its conformance to<br />
the US regulations.<br />
Finally, manufacturers that are not currently eligible<br />
under the program, or do not wish to participate at<br />
this time, are encouraged to volunteer to host joint<br />
1